<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18375178</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-0607</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>298</Volume>
            <Issue>5-6</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of medical microbiology : IJMM</Title>
          <ISOAbbreviation>Int J Med Microbiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bacillus anthracis: balancing innocent research with dual-use potential.</ArticleTitle>
        <Pagination>
          <StartPage>345</StartPage>
          <EndPage>364</EndPage>
          <MedlinePgn>345-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmm.2007.09.007</ELocationID>
        <Abstract>
          <AbstractText>Anthrax Euronet, a Coordination Action of the EU 6th Framework Programme, was designed to strengthen networking activities between anthrax research groups in Europe and to harmonise protocols for testing anthrax vaccines and therapeutics. Inevitably, the project also addressed aspects of the current political issues of biosecurity and dual-use research, i.e. research into agents of important diseases of man, livestock or agriculture that could be used as agents of bioterrorism. This review provides a comprehensive overview of the biology of Bacillus anthracis, of the pathogenesis, epidemiology and diagnosis of anthrax, as well as vaccine and therapeutic intervention strategies. The proposed requirement for a code of conduct for working with dual-use agents such as the anthrax bacillus is also discussed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hudson</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Health Protection Agency, Porton Down, Salisbury, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beyer</LastName>
            <ForeName>Wolfgang</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Böhm</LastName>
            <ForeName>Reinhard</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fasanella</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garofolo</LastName>
            <ForeName>Giuliano</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Golinski</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goossens</LastName>
            <ForeName>Pierre L</ForeName>
            <Initials>PL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hahn</LastName>
            <ForeName>Ulrike</ForeName>
            <Initials>U</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hallis</LastName>
            <ForeName>Bassam</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>King</LastName>
            <ForeName>Annemarie</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mock</LastName>
            <ForeName>Michèle</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montecucco</LastName>
            <ForeName>Cesare</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ozin</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tonello</LastName>
            <ForeName>Fiorella</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaufmann</LastName>
            <ForeName>Stefan H E</ForeName>
            <Initials>SH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2008</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Med Microbiol</MedlineTA>
        <NlmUniqueID>100898849</NlmUniqueID>
        <ISSNLinking>1438-4221</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022122">Anthrax Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037521">Virulence Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000881" MajorTopicYN="N">Anthrax</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022122" MajorTopicYN="N">Anthrax Vaccines</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001408" MajorTopicYN="N">Bacillus anthracis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037521" MajorTopicYN="N">Virulence Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2007</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2007</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2007</Year>
          <Month>9</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18375178</ArticleId>
        <ArticleId IdType="pmc">PMC7106442</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijmm.2007.09.007</ArticleId>
        <ArticleId IdType="pii">S1438-4221(08)00009-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abrami L., Reig N., van der Goot F.G. Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol. 2005;13:72–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15680766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abshire T.G., Brown J.E., Ezzell J.W. Production and validation of the use of gamma phage for identification of Bacillus anthracis. J. Clin. Microbiol. 2005;43:4780–4788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1234045</ArticleId>
            <ArticleId IdType="pubmed">16145141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baillie L.W.J. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 2006;101:594–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16907809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldari C.T., Tonello F., Paccani S.R., Montecucco C. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 2006;27:434–440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16861036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyer W. Vaccination strategies for anthrax prevention. Berl. Münch. Tierarztl. Wochenschr. 2004;117:508–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15584433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyer W., Bartling C., Neubauer H. Status quo of detection methods for Bacillus anthracis in clinical and environmental samples. Tieraerztl. Umschau. 2003;58:653–662.</Citation>
        </Reference>
        <Reference>
          <Citation>Biagini R.E., Sammons D.L., Smith J.P., MacKenzie B.A., Striley C.A.F., Semenova V., Steward-Clark E., Stamey K., Freeman A.E., Quinn C.P., Snawder J.E. Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin. Diag. Lab. Immunol. 2004;11:50–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC321348</ArticleId>
            <ArticleId IdType="pubmed">14715544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden E.D., Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 2006;38:240–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16429160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozue J., Cote C.K., Moody K.L., Welkos S.L. Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis. Infect. Immun. 2007;75:508–511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1828395</ArticleId>
            <ArticleId IdType="pubmed">17074844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Public Health. 1962;52:632–645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1522900</ArticleId>
            <ArticleId IdType="pubmed">18017912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brossier F., Levy M., Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 2002;70:661–664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC127709</ArticleId>
            <ArticleId IdType="pubmed">11796596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BWC, 2006a. Documents. The biological and toxin weapons convention and its status 〈http://www.opbw.org/〉.</Citation>
        </Reference>
        <Reference>
          <Citation>BWC, 2006b. Sixth Review Conference: Final Document 8 December 2006 〈http://www.opbw.org/〉.</Citation>
        </Reference>
        <Reference>
          <Citation>CDC, 2006. Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases: By Category 〈http://www.bt.cdc.gov/agent/agentlist-category.asp〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Collier R.J., Young J.A. Anthrax toxins. Annu. Rev. Cell Dev. Biol. 2003;19:45–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14570563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings R.T., Salowe S.P., Cunningham B.R., Wiltsie J., Park Y.W., Sonatore L.M., Wisniewski D., Douglas C.M., Hermes J.D., Scolnick E.M. A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc. Natl. Acad. Sci. USA. 2002;99:6603–6606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC124449</ArticleId>
            <ArticleId IdType="pubmed">11997440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dal Molin F., Tonello F., Ladant D., Zornetta I., Zamparo I., Di Benedetto G., Zaccolo M., Montecucco C. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. 2006;25:5405–5413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1636612</ArticleId>
            <ArticleId IdType="pubmed">17082768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dell’Aica I., Donà M., Tonello F., Piris A., Mock M., Montecucco C., Garbisa S. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. 2004;5:418–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1299029</ArticleId>
            <ArticleId IdType="pubmed">15031715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Vos V.  Proceedings of ARC-Ondersterpoort OIE International Congress with WHO – Co-sponsorship on Anthrax, Brucellosis, CBPP, Clostridial and Mycobacterial Diseases, 9–15 August 1998, Berg-en Dal, Kruger National Park. Sigma Press; Pretoria: 1998. Anthrax in the Kruger National Park: an ecological approach to the question whether anthrax is indigenous to the Kruger National Park; pp. 16–21.</Citation>
        </Reference>
        <Reference>
          <Citation>Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., Van de Woude G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998;280:734–737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9563949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang H., Xu L., Chen T.Y., Cyr J.M., Frucht D.M. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J. Immunol. 2006;176:6155–6161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16670324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanella A., Losito S., Trotta T., Adone R., Massa S., Ciuchini F., Chiocco D. Detection of anthrax vaccine virulence factors by polymerase chain reaction. Vaccine. 2001;19:4214–4218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11457547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fasanella, A., Schino, G., Schiavone, M.A., Losito, S., Buonavoglia, C., 2003. The presence of antibodies against Bacillus anthracis toxic factors in unvaccinated pastured sheep in Italy. In: Fifth International Conference on Anthrax, 30 March–3 April 2003, Nice, France.</Citation>
        </Reference>
        <Reference>
          <Citation>Fasanella A., Van Ert M., Altamura S.A., Garofolo G., Buonavoglia C., Leori G., Huynh L., Zanecki S., Keim P. Molecular diversity of Bacillus anthracis in Italy. J. Clin. Microbiol. 2005;43:3398–3401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1169099</ArticleId>
            <ArticleId IdType="pubmed">16000465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fouet A., Smith K.L., Keys C., Vaissaire J., Le Doujet C., Lévy M., Mock M., Keim P. Diversity among French Bacillus anthracis isolates. J. Clin. Microbiol. 2002;40:4732–4734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC154597</ArticleId>
            <ArticleId IdType="pubmed">12454180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gladstone G.P. Immunity to anthrax: protective antigen present in cell-free culture filtrates. Br. J. Exp. Pathol. 1946;27:394–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2065838</ArticleId>
            <ArticleId IdType="pubmed">20284522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glomski I.J., Fritz J.H., Keppler S.J., Balloy V., Chignard M., Mock M., Goossens P.L. Murine splenocytes produce inflammatory cytokines in a MyD88-dependent response to Bacillus anthracis spores. Cell. Microbiol. 2007;9:502–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16978234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glomski I.J., Corre J.-P., Mock M., Goossens P.L. IFN-γ producing CD4T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J. Immunol. 2007;178:2646–2650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17312104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., Kenner J., Deans L., Gurwith M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine. 2006;24:5950–5959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16797805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hering D., Thompson W., Hewetson J., Little S., Norris S., Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals. 2004;32:17–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15026022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmaster A.R., Ravel J., Rasko D.A., Chapman G.D., Chute M.D., Marston C.K., De B.K., Sacchi C.T., Fitzgerald C., Mayer L.W., Maiden M.C.J., Priest F.G., Barker M., Jiang L.X., Cer R.Z., Rilstone J., Peterson S.N., Weyant R.S., Galloway D.R., Read T.D., Popovic T., Fraser C.M. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc. Natl. Acad. Sci. USA. 2004;101:8449–8454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC420414</ArticleId>
            <ArticleId IdType="pubmed">15155910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu L.C., Park J.M., Zhang K., Luo J.L., Maeda S., Kaufman R.J., Eckmann L., Guiney D.G., Karin M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature. 2004;428:341–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15029200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hugh-Jones M.E. 1996–97 Global anthrax report. J. Appl. Microbiol. 1999;87:189–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10475945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hugh-Jones M.E., de Vos V. Anthrax and wildlife. Rev. Sci. Tech. 2002;2:359–389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11974621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ICH Steering Committee, 1996. ICH harmonised tripartite guidelines. Validation of analytical procedures: methodology Q2. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Step 4.</Citation>
        </Reference>
        <Reference>
          <Citation>Inglesby T.V., O’Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., Gerberding J., Hauer J., Hughes J., McDade J., Osterholm M.T., Parker G., Perl T.M., Russell P.K., Tonat K., for the Working Group on Civilian Biodefense  Anthrax as a biological weapon, 2002: updated recommendations for management. J. Am. Med. Assoc. 2002;287:2236–2252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11980524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keim P., van Ert M.N., Pearson T., Vogler A.J., Huynh L.Y., Wagner D.M. Anthrax molecular epidemiology and forensics: using the appropriate marker for different evolutionary scales. Infect. Genet. Evol. 2004;4:205–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15450200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim C., Gajendran N., Mittrucker H.W., Weiwad M., Song Y.H., Hurwitz R., Wilmanns M., Fischer G., Kaufmann S.H. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc. Natl. Acad. Sci. USA. 2005;102:4830–4835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC555714</ArticleId>
            <ArticleId IdType="pubmed">15772169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E., Kaufmann S.H. Defensin: a multifunctional molecule lives up to its versatile name. Trends Microbiol. 2006;14:428–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16908156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klee S.R., Nattermann H., Becker S., Urban-Schriefer M., Franz T., Jacob D., Appel B. Evaluation of different methods to discriminate Bacillus anthracis from other bacteria of the Bacillus cereus group. J. Appl. Microbiol. 2006;100:673–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16553722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch R.  Beiträge zur Biologie der Pflanzen. In: Cohn F., editor. Zweiter Band. Zweites Heft; Breslau: 1876. pp. 277–310. (in German)</Citation>
        </Reference>
        <Reference>
          <Citation>Koehler T.M., editor. Vol. 271. Springer; Berlin: 2002.  (Anthrax. Curr. Top. Microbiol. Immunol.).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12224521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leendertz F.H., Ellerbrok H., Boesch C., Couacy-Hymann E., Matz-Rensing K., Hakenbeck R., Bergmann C., Abaza P., Junglen S., Moebius Y., Vigilant L., Formenty P., Pauli G. Anthrax kills wild chimpanzees in a tropical rainforest. Nature. 2004;430:451–452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15269768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA. 1982;79:3162–3166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC346374</ArticleId>
            <ArticleId IdType="pubmed">6285339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lista F., Faggioni G., Valjevac S., Ciammaruconi A., Vaissaire J., le Doujet C., Gorge O., de Santis R., Caratoli A., Ciervo A., Fasanella A., Orsini F., D’Amelio R., Pourcel C., Cassone A., Vergnaud G. Genotyping of Bacillus anthracis strains based on automated capillary 25-loci multiple locus variable-number tandem repeats analysis. BMC Microbiol. 2006;6:33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1479350</ArticleId>
            <ArticleId IdType="pubmed">16600037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Little S.F. Anthrax vaccines – a development update. Biodrugs. 2005;19:233–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16128606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longchamp P., Leighton T. Molecular recognition specificity of Bacillus anthracis spore antibodies. J. Appl. Microbiol. 1999;87:246–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10475958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lord, A.M., 2001. A brief history of anthrax. Office of the Public Health Service Historian 〈http://lhncbc.nlm.nih.gov/apdb/phsHistory/resources/pdf/anthrax.pdf〉.</Citation>
        </Reference>
        <Reference>
          <Citation>Mabry R., Brasky K., Geiger R., Carrion R., Jr., Hubbard G.B., Leppla S., Patterson J.L., Georgiou G., Iverson B.L. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin. Vaccine Immunol. 2006;13:671–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1489546</ArticleId>
            <ArticleId IdType="pubmed">16760326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marston C.K., Gee J.E., Popovic T., Hoffmaster A.R. Molecular approaches to identify and differentiate Bacillus anthracis from phenotypically similar Bacillus species isolates. BMC Microbiol. 2006;6:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1413540</ArticleId>
            <ArticleId IdType="pubmed">16515693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer-Scholl A., Hurwitz R., Brinkmann V., Schmid M., Jungblut P., Weinrauch Y., Zychlinsky A. Human neutrophils kill Bacillus anthracis. PLoS Pathog. 2005;119:216–221.</Citation>
        </Reference>
        <Reference>
          <Citation>Mikesell P., Ivins B.E., Ristroph J.D., Dreier T.M. Evidence for plasmid mediated toxin production in Bacillus anthracis. Infect. Immun. 1983;39:371–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC347948</ArticleId>
            <ArticleId IdType="pubmed">6401695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitzmain M.B. Experimental insect transmission of anthrax. Public Health Rep. 1914;29:75–77.</Citation>
        </Reference>
        <Reference>
          <Citation>Mock M., Fouet A. Anthrax. Annu. Rev. Microbiol. 2001;55:647–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11544370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C., Tonello F., Zanotti G. Stop the killer: how to inhibit the anthrax lethal factor metalloprotease. Trends Biochem. Sci. 2004;29:282–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15276179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris H. Some carriers of anthrax infection. J. Am. Vet. Med. Assoc. 1920;56:606–608.</Citation>
        </Reference>
        <Reference>
          <Citation>Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6606682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muehlbauer S., Evering T., Bonuccelli G., Squires R., Ashton A., Porcelli S., Lisanti M., Brojatsch J. Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle. 2007;6:758–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17374996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishi J.S., Dragon D.C., Elkin B.T., Mitchell J., Ellsworth T.R., Hugh-Jones M.E. Emergency response planning for anthrax outbreaks in bison herds of northern Canada: a balance between policy and science. Ann. NY Acad. Sci. 2002;969:245–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12381599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okinaka R., Pearson T., Keim P. Anthrax, but not Bacillus anthracis? PloS Pathog. 2006;2:e122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1657067</ArticleId>
            <ArticleId IdType="pubmed">17121463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozin A., Bade K., Kaufmann S.H.E. US restrictions limit anthrax networking. Nature. 2004;431:897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15496891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paccani S.R., Tonello F., Ghittoni R., Natale M., Muraro L., D’Elios M.M., Tang W., Montecucco C., Baldari C.T. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005;201:325–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213032</ArticleId>
            <ArticleId IdType="pubmed">15699068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papaparaskevas J., Houhoula D.P., Papadimitriou M., Saroglou G., Legakis N.J., Zerva L. Ruling out Bacillus anthracis. Emerg. Infect. Dis. 2004;10:732–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3323068</ArticleId>
            <ArticleId IdType="pubmed">15200872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasteur L. Compte rendu sommaire des expériences faites à Pouilly-le-Fort, près Melun, sur la vaccination charbonneuse. C.R. Acad. Sci. 1881;92:1378–1383. (in French)</Citation>
        </Reference>
        <Reference>
          <Citation>Phipps A.J., Premanandan C., Barnewall R.E., Lairmore M.D. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microb. Mol. Biol. Rev. 2004;68:617–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC539006</ArticleId>
            <ArticleId IdType="pubmed">15590776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piris Gimenez A., Wu Y.-Z., Paya M., Delclaux C., Touqui L., Goossens P.L. High bactericidal efficiency of type IIA phospholipase A2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J. Immunol. 2004;173:521–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15210813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piris-Gimenez A., Paya M., Lambeau G., Chignard M., Mock M., Touqui L., Goossens P.L. In vivo protective role of human group IIA phospholipase A2 against experimental anthrax. J. Immunol. 2005;175:6786–6791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16272335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pini A., Runci Y., Falciani C., Lelli B., Brunetti J., Pileri S., Fabbrini M., Lozzi L., Ricci C., Bernini A., Tonello F., Dal Molin F., Neri P., Niccolai N., Bracci L. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo. Biochem. J. 2006;395:157–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1409687</ArticleId>
            <ArticleId IdType="pubmed">16398644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redmond C., Baillie L.W.J., Hibbs S., Moir A.J.G., Moir A. Identification of proteins in the exosporium of Bacillus anthracis. Microbiology. 2004;150:355–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14766913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhie G.-E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA. 2003;100:10925–10930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196904</ArticleId>
            <ArticleId IdType="pubmed">12960361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivera V.R., Merrill G.A., White J.A., Poli M.A. An enzymatic electrochemiluminescence assay for the lethal factor of anthrax. Anal. Biochem. 2003;321:125–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12963063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi-Paccani S., Tonello F., Patrussi L., Capitani N., Simonato M., Montecucco C., Baldari T.C. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signaling. Cell. Microbiol. 2007;9:924–929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17087730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saile E., Koehler T.M. Bacillus anthracis multiplication, persistence and genetic exchange in the rhizosphere of grass plants. Appl. Environ. Microbiol. 2006;72:3168–3174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472387</ArticleId>
            <ArticleId IdType="pubmed">16672454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneerson R., Kubler-Kielb J., Liu T.-Y., Dai Z.-D., Leppla S.H., Yergey A., Backlund P., Shiloach J., Majadly F., Robbins J.B. Poly(γ-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA. 2003;100:8945–8950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC166418</ArticleId>
            <ArticleId IdType="pubmed">12857944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scobie H.M., Young J.A. Interactions between anthrax toxin receptors and protective antigen. Curr. Opin. Microbiol. 2005;8:106–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15694864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scorpio A., Blank T.E., Day W.A., Chabot D.J. Anthrax vaccines: Pasteur to present. Cell. Mol. Life Sci. 2006;63:2237–2248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16964578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Y., Zhukovskaya N.L., Zimmer M.I., Soelaiman S., Bergson P., Wang C.R., Gibbs C.S., Tang W.J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 2004;101:3242–3247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC365774</ArticleId>
            <ArticleId IdType="pubmed">14978283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steichen C., Chen P., Kearney J.F., Turnbough C.L., Jr. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J. Bacteriol. 2003;185:1903–1910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC150129</ArticleId>
            <ArticleId IdType="pubmed">12618454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steichen C.T., Kearney J.F., Turnbough C.L., Jr. Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J. Bacteriol. 2005;187:5868–5876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1196169</ArticleId>
            <ArticleId IdType="pubmed">16109927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne M. The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis. Onderstepoort J. Vet. Sci. Anim. Ind. 1939;13:307–312.</Citation>
        </Reference>
        <Reference>
          <Citation>Sterne M. Distribution and economic importance of anthrax. Fed. Proc. 1967;26:1493–1495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6069280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sylvestre, P., Tosi-Couture, E., Mock, M., 2001. Analysis of Bacillus anthracis spore surface antigens with monoclonal antibodies. In: Proceedings of the Fourth International Conference on Anthrax, Annapolis, MD, USA, June 10–13, 2001, p. 30.</Citation>
        </Reference>
        <Reference>
          <Citation>Sylvestre P., Couture-Tosi E., Mock M. A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol. Microbiol. 2002;45:169–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12100557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sylvestre P., Couture-Tosi E., Mock M. Polymorphism in the collagen-like region of the Bacillus anthracis BclA protein leads to variation in exosporium filament length. J. Bacteriol. 2003;185:1555–1563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC148075</ArticleId>
            <ArticleId IdType="pubmed">12591872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sylvestre P., Couture-Tosi E., Mock M. Contribution of ExsFA and ExsFB proteins to the localization of BclA on the spore surface and to the stability of the Bacillus anthracis exosporium. J. Bacteriol. 2005;187:5122–5128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1196022</ArticleId>
            <ArticleId IdType="pubmed">16030205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sylvestre P., Glomski I.J., Couture-Tosi E., Goossens P.L., Mock M.  Spore surface components and protective immunity to Bacillus anthracis. In: Georgiev V.S., editor. National Institute of Allergy and Infectious Diseases: Frontiers In Research 2006. Humana Press; Totawa, NJ: 2008. </Citation>
        </Reference>
        <Reference>
          <Citation>Tonello F., Seveso M., Marin O., Mock M., Montecucco C. Pharmacology: screening inhibitors of anthrax lethal factor. Nature. 2002;418:386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12140548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tourasse N.J., Helgason E., Økstad O.A., Hegna I.K., Kolstø A.B. The Bacillus cereus group: novel aspects of population structure and genome dynamics. J. Appl. Microbiol. 2006;101:579–593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16907808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tournier J.-N., Quesnel-Hellmann A., Mathieu J., Montecucco C., Tang W.-J., Mock M., Vidal D.R., Goossens P.L. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 2005;174:4934–4941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15814721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turnbull P.C., Bell R.H., Saigawa K., Munyenyembe F.E., Mulenga C.K., Makala L.H. Anthrax in wildlife in the Luangwa Valley, Zambia. Vet. Rec. 1991;17:399–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1907048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner A.J., Galvin J.W., Rubira R.J., Condron R.J., Bradley T. Experiences with vaccination and epidemiological investigations on anthrax outbreak in Australia in 1997. J. Appl. Microbiol. 1999;87:294–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10475972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turrel M.J., Knudson G.B. Mechanical transmission of Bacillus anthracis by stable flies (Stomoxys calcitrans) and mosquitoes (Aedes aegypti and Aedes taeniorhynchus) Infect. Immun. 1987;55:1859–1961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC260614</ArticleId>
            <ArticleId IdType="pubmed">3112013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Ert M.N., Easterday W.R., Huynh L.Y., Okinaka R.T., Hugh-Jones M.E., Ravel J., Zanecki S.R., Pearson T., Simonson T.S., U’Ren J.M., Kachur S.M., Leadem-Dougherty R.R., Rhoton S.D., Zinser G., Farlow J., Coker P.R., Smith K.L., Wang B., Kenefic L.J., Fraser-Liggett C.M., Wagner D.M., Keim P. Global genetic population structure of Bacillus anthracis. PLoS ONE. 2007;2:e461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1866244</ArticleId>
            <ArticleId IdType="pubmed">17520020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale G., Pellizzari R., Recchi C., Napoletani G., Mock M., Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998;248:706–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9703991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000;352:739–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1221512</ArticleId>
            <ArticleId IdType="pubmed">11104681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Mulakala C., Ward S.C., Jung G., Luong H., Pham D., Waring A.J., Kaznessis Y., Lu W., Bradley K.A., Lehrer R.I. Retrocyclins kill bacilli and germinating spores and inactivate anthrax lethal toxin. J. Biol. Chem. 2006;281:32755–32764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2440672</ArticleId>
            <ArticleId IdType="pubmed">16790431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei W., Lu Q., Chaudry G.J., Leppla S.H., Cohen S.N. The LDL receptor-related protein LPR6 mediates internalization and lethality of anthrax toxin. Cell. 2006;124:1141–1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16564009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welkos S.L., Friedlander A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 1988;4:53–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3143893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witkowski J.A., Parish L.C. The story of anthrax from antiquity to the present: a biological weapon of nature and humans. Clin. Dermatol. 2002;20:336–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12208620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO, 1998. Guidelines for the Surveillance and Control of Anthrax in Humans and Animals, third ed., WHO/EMC/ZDI./98.6. World Health Organization, Geneva.</Citation>
        </Reference>
        <Reference>
          <Citation>Young J., Bromberg-White J., Zylstra C., Church J., Boguslawski E., Resau J., Williams B., Duesbery N. LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog. 2007;3:e27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1808072</ArticleId>
            <ArticleId IdType="pubmed">17335347</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
